

1 **Title page**

2

3 **To what extent is the altitude at which we live**  
 4 **associated with 10-year cardiovascular risk?**

5

6 Andrea Cevallos Guerrero<sup>1¶</sup>, Heidi Angela Fernández<sup>1¶</sup>, Ángela León-Cáceres<sup>3,4¶</sup>,  
 7 Luciana Armijos-Acurio<sup>2</sup>, Carlos Erazo<sup>3</sup>, Ruth Jimbo-Sotomayor<sup>2</sup>, Hugo Pereira-  
 8 Olmos<sup>3</sup>, Henry Pineda-Abarca<sup>5</sup>, Erika Quishpe-Narváez<sup>3</sup>, Xavier Sánchez<sup>2</sup>, Carmenza  
 9 Sevilla<sup>3</sup>, Betzabé Tello<sup>3</sup>, Ana Torres-Castillo<sup>3</sup>, Tatiana Villacrés<sup>3</sup>, Iván Dueñas-Espín<sup>3&</sup>

10 <sup>1</sup> Department of Internal Medicine, Eugenio Espejo Hospital, Gran Colombia Street,  
 11 Quito, Ecuador.

12 <sup>2</sup> Centro de Investigación para la Salud en América Latina (CISeAL), Facultad de  
 13 Medicina, Pontificia Universidad Católica del Ecuador, Quito, Ecuador.

14 <sup>3</sup> Instituto de Salud Pública, Facultad de Medicina, Pontificia Universidad Católica del  
 15 Ecuador (PUCE), Quito, Ecuador.

16 <sup>4</sup> Heidelberg Institute of Global Health, Faculty of Medicine, University of Heidelberg,  
 17 Heidelberg, Germany; Tropical Herping, Quito-Ecuador.

18 <sup>5</sup> PUCESalud, Pontificia Universidad Católica del Ecuador, Quito, Pichincha, Ecuador.

19 \* Correspondence author

20 E-mail: igduenase@puce.edu.ec

21 ¶ These authors contributed equally to this work.

22 Number of words in the abstract: 247, number of words in the main text: 3990, number  
 23 of figures: 1, number of tables: 2, number of supporting information archives: 7;  
 24 number of references: 47.

## 25 **Abstract**

### 26 **Introduction:**

27 There is evidence that demonstrates lower incidence rates of cardiometabolic factors at  
 28 the highlands. There are no studies which correlate the altitude with formally calculated  
 29 cardiovascular risk by a meter-by-meter approach. Under the hypothesis that  
 30 cardiovascular risk is inversely associated with altitude, this study was aimed to assess  
 31 such association.

### 32 **Materials and methods**

33 Cross sectional study using data from the Ecuadorian National Health Survey of 2012.  
 34 We analyzed available information of adults of  $\geq 40$  to 60 years old who have  
 35 sociodemographic, anthropometric, cardiovascular risk factors, and laboratory  
 36 biomarkers that were included in the survey. We assessed the independent association  
 37 between altitude of the housing in which survey participants lived at, on a meter-by-  
 38 meter approach, and cardiovascular health risk at ten years, formally calculated by  
 39 Framingham equations.

### 40 **Results**

41 Linear regression model showed that participants had 0.0005 % less probability of  
 42 developing cardiovascular disease at 10 years *per* each increase in a meter in the altitude  
 43 that participants live at ( $p < 0.001$ ), adjusted for sex, age, ethnicity, educational level,  
 44 availability of social security, immigrants in family, area, income quintile,  
 45 overcrowding ( $\geq 7$  inhabitants in the house), any alcohol consumption, history of  
 46 hypertension, body mass index, hematocrit, and triglycerides.

## 47 Conclusion

48 From a public health perspective, altitude at which individuals live is an important  
 49 health determinant of cardiovascular risk. Specifically, *per* each increase of 1000 m in  
 50 the altitude that people live at, there is a reduction of almost half a percentual point in  
 51 the cardiovascular risk at 10 years.

52  
 53 **Keywords:** epidemiology, altitude, cardiovascular risk, cross sectional study.  
 54

## 55 Introduction

56 Cardiovascular diseases (CVDs) are the leading cause of death worldwide, claiming the  
 57 lives of approximately 17.9 million people annually [1]. They account for roughly 50%  
 58 of non-communicable disease deaths [2,3] and more than three quarters of these deaths  
 59 take place in low- and middle-income countries [4]. CVDs include coronary heart  
 60 disease and stroke, among the most important, all of which produce substantial health  
 61 and economic burden globally [2].

62 It is widely accepted that CVDs are closely related to social determinants (SDs) of  
 63 health, which are defined by the World Health Organization (WHO) as “circumstances  
 64 in which people are born, grow, live, work, and age, and the systems put in place to deal  
 65 with illnesses” [5–7]. Scientific evidence has shown that SDs such as socioeconomic  
 66 status, demographic characteristics, education, work environment, health care services  
 67 and housing may be associated with the development of CVDs; however they are not  
 68 routinely acknowledged during risk assessment in clinical practice [8–10]. At the same  
 69 time, a lot of efforts are directed to identify and treat individual-level risk factors [11].  
 70 In this regard, analyzing SDs is crucial for a complete cardiovascular clinical  
 71 assessment.

72 Environmental determinants are key risk factors linked to CVDs. Although they are  
 73 generally understudied and overlooked [10], growing evidence suggests that variations  
 74 in factors such as temperature, altitude, climate and pollution, among others, remain  
 75 significant determinants of cardiovascular risk [12,13]. Specifically, altitude continues  
 76 to be a factor closely associated with cardiovascular risk. Several studies support an  
 77 inverse association between altitude and cardiovascular risk factors [14–18], but the  
 78 required time of exposure for a protective effect is unclear.

79 Overall, there are two scenarios, a rapid change to high altitude and a progressive  
80 adaptation to it. It is well known that patients with CVDs traveling from areas at sea  
81 level to the ones at high altitude –defined as the terrestrial elevation at which oxygen  
82 hemoglobin saturation decreases below 90%; corresponding to an altitude of about 2500  
83 m– [19] have an increased mortality risk as a consequence of lower physiological  
84 reserves [20]. Several explanations have been proposed. Individuals with a reduced  
85 physiological reserve and subsequent difficulty to adapt to hypoxic conditions at high  
86 altitudes can present decreased functional capacity due to impaired pulmonary gas  
87 exchange and/or cardiac output. However, there is scarce epidemiological data  
88 discussing morbidity after traveling to altitude areas among this population [20].

89 Considering that about 400 million people live at an altitude of over 1500 meters above  
90 sea level and around 150 million people live in regions higher than 2500 m [21,22],  
91 altitude remains as an important health determinant that requires proper analysis. This  
92 population has managed to survive at high altitudes for generations; therefore, contrary  
93 to the above-mentioned statement, scientific evidence suggest that they must have  
94 developed significant adaptations to lower oxygen levels to survive [13,23].

95 Long term exposure to high altitudes seems to be associated with a lower incidence of  
96 obesity [14,17], high blood pressure [16,24], metabolic syndrome [15,18], diabetes [15],  
97 and, even, a better expectancy of life [25]. In fact, living at a geographically higher  
98 elevation was also associated with a lower risk of developing metabolic syndrome [18].  
99 Specifically, no studies have focused on the association between formal cardiovascular  
100 risk estimation and altitude, and most of those studies are only focusing on the  
101 association between just a few categories of altitude, making it difficult to understand  
102 the association and its real magnitude on a meter-by-meter basis.

103 With this background we hypothesized that altitude is inversely related with  
104 cardiovascular risk. Using the databases of the Ecuadorian national health survey of  
105 2012 we aimed to assess the association between altitude and cardiovascular risk among  
106 the Ecuadorian adult population, of  $\geq 40$  to 60 years old on a meter-by-meter basis.

## 107 **Materials and Methods**

### 108 **Design**

109 Cross sectional study using data from the Ecuadorian National Health Survey (NHS) of  
110 2012.

### 111 **Population and databases**

112 We included in our study available information of adults of  $\geq 40$  to 60 years old who  
113 have sociodemographic, anthropometric, cardiovascular risk factors, and laboratory  
114 biomarkers that were included in the in NHS in 2012 (see flowchart in the **S1 Figure**).

115 The Ecuadorian national health survey was a cross-sectional study conducted in 2012  
116 which involved nationally representative samples of the civilian noninstitutionalized  
117 Ecuadorian population, the details regarding the survey could be found elsewhere  
118 [15,26]. The survey was conducted by the National Institute of Statistics and Census  
119 using a stratified, multistage cluster design [26].

### 120 **Measurements**

121 We included in our analyses sex, age, ethnicity, educational level, availability of social  
122 security, immigrants in family, area, income quintile, overcrowding ( $\geq 7$  inhabitants in  
123 the house), any alcohol consumption, history of hypertension, body mass index,

124 hematocrit, and triglycerides. Ethnicity was self-reported and classified as Indigenous,  
125 Afroecuatorians, Montubios and Mestizos. Standardized blood pressures were obtained  
126 by sphygmomanometer, and mean blood pressures from the last 2 measurements were  
127 used in the Ecuadorian NHS. Blood lipids were measured enzymatically. Detailed  
128 specimen collection and processing instructions are described in the NHS [26].  
129 Anthropometry was assessed in a standardized way, and body mass index (BMI; in  
130  $\text{kg/m}^2$ ) was calculated.

131 The main explanatory variable was altitude on a meter-by-meter assessment, using  
132 information from the altitude of the housing in which survey participants lived [15,26].  
133 Altitude was obtained by georeferencing, according to the methods that have been  
134 described elsewhere [26].

### 135 **Cardiovascular Health Metrics**

136 Cardiovascular health metrics included blood pressure, blood glucose, and lipid profile.  
137 High blood pressure was defined with a self-reported history of hypertension, diabetes  
138 mellitus was defined when the fasting glucose was higher or equal to 126 mg/ dL [27].  
139 Risk of CHD and stroke or CVD at 10 years were calculated by Framingham equations  
140 (available at <http://cvrisk.mvm.ed.ac.uk/help.htm>) [28,29].

### 141 **Sample considerations and statistical analyses**

142 Using the prevalence of high blood pressure as the methodological variable, a random  
143 sample of 3601 individuals is sufficient to estimate, with a confidence of 95% and a  
144 precision of +/- 1 percentage units, a population percentage that will foreseeably be  
145 around 9.3% [26]. In percentage of necessary replacements, it has been foreseen that it  
146 will be 10%. The final sample was 3661 participants included in the study assuring



147 statistical power (see Figure 1 and the online supplementary material for further details)  
148 (see). The sample calculation was performed using the GRANMO population calculator  
149 <http://www.imim.cat/ofertadeserveis/software-public/granmo/> [30].

150 First, we tested the bivariate associations between altitude (both categorized four  
151 quartiles and as continuous variables) and the percentage of cardiovascular risk (CHD,  
152 Stroke and CVD) at 10 years, using analysis of variance and linear regression. Despite  
153 altitude and cardiovascular risk were non-normally distributed (**S1 and S2 Figures**),  
154 and prior to building multivariable models, we used generalized additive model  
155 analyses to test whether the shape of the association between altitude and cardiovascular  
156 risk was linear.

157 Then, we used multivariable linear regression to assess the independent effect of  
158 altitude on CVD. We tested a list of potential confounders, including age, sex, ethnicity,  
159 economic quintile status, social security availability, overcrowding ( $\geq 7$  inhabitants *per*  
160 home), emigration, smoking and alcohol consumption, hypertension, hematocrit, and  
161 triglycerides. From these variables, we built a “saturated model”, which included: (i)  
162 variables independently related to the exposure or the outcome (p-value  $< 0.05$ ), or that  
163 modified ( $>10\%$  change in coefficient) the estimates for the remaining variables, and  
164 (ii) those variables that were considered important to all researchers. Then, we built a  
165 “parsimonious model” using a backward stepwise elimination process from the  
166 “saturated model” removing variables (one at a time) if Wald’s p-value  $< 0.05$ . We  
167 tested both models, saturated versus parsimonious by the likelihood ratio test which was  
168 used to choose the final model and for the interpretation of the results. We tested  
169 goodness-of-fit of the final models.

170 We also built logistic regression models, including all significant variables that were  
171 identified in the final linear regression models, using the dichotomous outcome variable  
172 “high cardiovascular risk” when there was  $\geq 20\%$  risk of CHD and stroke or CVD at 10  
173 years.

174 We performed several sensitivity analyses. Thus, we ran the final model stratifying by  
175 sex and by excluding (i) those who were living at less than 53 m (first quartile of  
176 altitude), (ii) those who were living at higher areas than 2635 m (fifth quartile of  
177 altitude), (iii) those with self-reported diagnosis of hypertension, and (iv) those with  
178 elevated LDL cholesterol ( $\geq 160$  mg/dL) [31].

179 To identify potential effect modification, we stratified main analyses according to sex,  
180 history of hypertension, and smoking status. The analyses were performed using Stata  
181 16.1 (Stata Statistical Software: Release 16.1; StataCorp LP, College Station, TX,  
182 USA).

183 The NHS which we used was performed in 2012. The specific ethical issues have been  
184 described elsewhere [26].

## 185 **Results**

186 A total of 3661 patients were included. Most patients were women (69%), with a mean  
187 (SD) age of 45 (7) years, the majority were mestizo population (83%), with primary or  
188 lesser education (50%), only 35% had social security, mostly from urban areas (62%).  
189 The median (P25 to P75) altitude at which participants lived was 843 (53 to 2635) m.  
190 Regarding harmful health-related habits, most participants (90%) stated they have  
191 consumed alcohol at some point during their lifetime. There was also a tobacco  
192 smoking prevalence of 45%. The prevalence of self-reported history of hypertension

193 and diabetes (as measured by fasting glucose  $\geq 126$  mg /dL) was 24% and 5%,  
194 respectively. Mean (SD) BMI was 28 (5) kg/m<sup>2</sup>, and mean total cholesterol was 196  
195 (41) mg/dL (**S1 Table**). The prevalence of high ( $\geq 20\%$ ) cardiovascular risk (stroke or  
196 coronary heart disease) at 10 years was 7%.

197 In the bivariate analysis, increasing altitude was associated with lower median  
198 percentage cardiovascular risk at 10 years, as it was 8% in the lowest quartile of  
199 altitude ( $< 54$  m) and 6% in the higher quartile of altitude ( $> 2635$  m) ( $p$ -value $< 0.001$ ),  
200 and with a lower median risk of stroke or coronary heart disease at 10 years, being 7%  
201 in the lowest quartile of altitude ( $< 54$  m) and 5% in the higher quartile of altitude  
202 ( $> 2635$  m) ( $p$ -value $< 0.001$ ). Additionally, in the crude linear regression model we  
203 found a linear dose-response shape, with a reduction of -0.0005 percentual points in  
204 CVD risk *per* each increase in a meter in the altitude at which participants live,  $p$ -  
205 trend $< 0.001$ ; interestingly, each cardiometabolic risk factor seems to improve with  
206 increasing altitude (**Table 1 and Table 2**).

207 In the multivariable saturated model [adjusted for sex, age, ethnicity, educational level,  
208 availability of social security, immigrants in family, area, income quintile,  
209 overcrowding ( $\geq 7$  inhabitants in the house), any alcohol consumption, history of  
210 hypertension, BMI, hematocrit, and triglycerides] participants had 0.0004 % less  
211 probability of developing cardiovascular (stroke and coronary heart disease) disease at  
212 10 years *per* each increase in a meter in the altitude that participants live at ( $p < 0.001$ )  
213 (**Table 2 and Figure 1**). This association persisted in the parsimonious model ( $\beta =$   
214 0.0005%,  $p = 0.02$ ). The effect of altitude on cardiovascular risk did not change after  
215 stratifying by sex (**S3 Table**).

216 The exclusion of people who were living at less than 53 m of altitude, those who were

217 living at higher altitudes than 2635 m, people with self-reported diagnosis of  
218 hypertension, and those with elevated LDL cholesterol ( $\geq 160$  mg/dL) in the model did  
219 not modify the estimate of the association between altitude and cardiovascular risk (**S4**  
220 **Table**). Linear regression goodness of fit tests did not reveal any significant  
221 abnormality.

## 222 **Discussion**

### 223 **Main findings**

224 We found that, *per* each increase of 1000 m in the altitude that people live at, there is a  
225 reduction of almost half a percentual point in the cardiovascular risk at 10 years. This  
226 finding could be considered of little relevance from a clinical point of view, but altitude  
227 may be significant from a public health perspective, in terms of focusing with enhanced  
228 strategies of health promotion and primary prevention against CVDs in the population  
229 of coastal regions. In that regard, we share the criteria of Lopez-Pascual and cols. [18]  
230 about the potential existence of the Rose prevention paradox, where factors that make a  
231 small difference to the population distribution may be more important than factors that  
232 have a clinical impact on a small number of people [27].

### 233 **Contrast with scientific evidence**

234 As several studies have demonstrated, altitude and specifically high altitude, is an  
235 important determinant of health outcomes, including cardiovascular disease. It is known  
236 that altitude-associated conditions may have different impacts on risk factors which can  
237 influence the development of different diseases; as well as having consequences on life  
238 expectancy and mortality [32]. For instance, a study conducted in the United States  
239 concluded that altitude may have protective effects on cardiovascular diseases and

harmful effects on chronic pulmonary disease (COPD), with a dose-response relationship. Other authors [33], in a longitudinal, census-based record linkage study commented on the protective effect of living at higher altitude on coronary heart disease and stroke mortality; however, this study explained that this effect might have appeared due to climate-related factors and not necessarily due to classic cardiovascular risk factors. Another study in rural Greece concluded that living in mountainous areas have a possible protective effect from total and coronary mortality; this was explained by the possible effects of physical activity [34].

Even if a positive relation appears in some studies, a systematic review described that intermittent exposure to high altitude among workers increased the risk of CVDs. According to Burtcher, “COPD might be reduced when living at higher elevations but when suffering from COPD the mortality risk rises. Thus, COPD patients, especially when disease progresses would benefit from moving down to more oxygen rich sea level regions” [32]. As several circulatory changes occur during exposure to high altitude, some studies [19,35] concluded on the negative effect of altitude on populations suffering from pre-existing cardiovascular diseases.

It is not the first time that altitude has been linked with cardiovascular risk [17,25]. Some studies show that native Tibetans and Nepalese Sherpas rarely have systolic hypertension, having also lower levels of cholesterol [11]. A cohort study within the German-speaking part of Switzerland found a decreasing mortality by coronary heart disease or stroke when altitude increases. Some possible explanations to this finding are related to other risk factors such as pollution, since air pollution diminishes within increasing altitude. Another reason to support this fact is that diet could also be beneficial since food produced at higher altitudes might be richer in protective nutrients like omega 3 and vitamin D in dairy products [33].

265 Populations living in high lands experienced significant anatomic, physiological, and  
 266 metabolic adaptation to cold temperature and low oxygen levels [13]. Other studies  
 267 have suggested that living at high altitude may confer highlanders with protection  
 268 against cardiovascular risk factors like dyslipidemia as well as CVDs such as  
 269 hypertension and coronary ischemic disease [36,37]. The physiological changes are  
 270 mostly due to ambient hypoxia, which occurs because of low atmospheric pressure,  
 271 whilst the percentage of oxygen remains the same [14,38]. In Ecuador, there could also  
 272 be an impact in lower cardiovascular risk, due to seasonal and latitudinal location.  
 273 Studies have found that being close to the equator decreased blood pressure due to the  
 274 correlation between Vitamin D absorption associated with UVB radiation [13].

275 Initial altitude-related adaptive changes include increased heart rate, cardiac output,  
 276 hyperventilation, and, subsequently, increased red blood cell mass [14,19,39].  
 277 Eventually, a steady state could be reached, possibly due to the beneficial effects of  
 278 ensuing cardiovascular, respiratory, and muscular adaptation mechanisms. However, it  
 279 is important to note that there is substantial interindividual variability in the  
 280 cardiovascular response to hypoxia [19]. In a study conducted by Sherpa et al, the  
 281 female individuals living at high altitude had very low coronary heart disease risk, in  
 282 addition to variations in the lipid profile of their population, namely a higher prevalence  
 283 of hypertriglyceridemia in men [40]. Despite there is some evidence suggesting that  
 284 there is a direct association between altitude and cardiometabolic risk [19,35,41,42], our  
 285 study strongly supports the idea that altitude is a determinant of cardiovascular health in  
 286 an inverse association when the exposure is prolonged.

287 Regarding the association between education and cardiovascular disease, we could not  
 288 corroborate that link; and, although several studies have found that lower educational  
 289 level is associated with higher cardiovascular risk, this relationship may vary depending

on the analyzed cohort [43]. Furthermore, one possible explanation is that the association between education and CVD risk is mediated by obesity, metabolic syndrome, and high blood pressure [44]. Another explanation is that in Ecuador, the economic quintile could be a strong determinant of CVD risk, as it is seen in our analyses in which the poorest group had less CVD risk; thus, socioeconomic status is an important influence factor of CVD risk.

## **Public health implications of our findings**

Even though the clinical advice to live near the sea has become popular among cardiologists and other medical specialists when a patient suffers from cardiopulmonary diseases, our study gives valuable information that could guide and further analyse the need to reconsider or personalize this advice. Clearly, for patients with cardiovascular diseases who regularly live at low altitudes, there is sufficient evidence to not recommend trips to high altitudes, given the limited cardiopulmonary reserve which could become compromised and would probably increase their CVD risk; however, after our study, we can assume that individuals residing in elevated areas have a lower risk of developing CVDs. Consequently, considerations need to be made about exposing a patient to prolonged periods of time at high altitudes to receive the benefits of the stress produced to avoid cardiovascular disease.

Currently, it is not possible to make an appropriate recommendation for individual-based benefits for at-risk population of CVDs about exposure to high altitudes, but future studies are needed to explore whether simulated altitude conditions may have potential protective, or even, therapeutic interventions for cardiovascular risk [13]. It would be important to state that people who do not have a CVD can continue living at high altitude areas to enhance other health promotion and prevention measures against

314 CVDs, contrary to the ones who have a CVD who could be advised to live at the sea  
315 level to improve pulmonary health problems.

316 Perhaps in the future, this evidence could be the door towards the development of new  
317 strategies for health promotion and primary prevention, possibly, also for treatments  
318 stratified to the altitude of the residential areas of different populations.

319 At the same time, the strengthening of the high-altitude food systems could be a way of  
320 promoting and spreading dietary practices of high-altitude regions. Mediterranean diet  
321 has been popularized among physicians, but it has serious limitations regarding its cost  
322 and availability in low- and middle-income countries like Ecuador. This study could be  
323 a useful element to think about promoting public health measures aimed to improve  
324 conditions for groups living in low-altitude areas. For example, to improve access to  
325 nutrients and educational policies directed to provide conditions to reduce the risk of  
326 CVDs, among others.

### 327 **Strengths and limitations**

328 We are aware that this is a cross sectional study; therefore, it is not possible to establish  
329 a causal relationship between altitude and cardiovascular risk. At the same time, this is  
330 the first study, to our knowledge, which considered the impact of altitude on a meter-  
331 by-meter basis and its relation on formally calculated cardiovascular risk. In addition,  
332 this study considers the potential residual confounders of several factors from social  
333 demographic, economic, biochemical, and anthropometric measures, reducing the risk  
334 of confounding bias.

335 Regarding the possibility of residual confounding of physical activity (PA) in the  
336 association between altitude and CVDs risk, the amount of PA across altitude strata



could be different, researchers have described significant adaptations to high altitude, in terms of body weight reduction, regardless of the amount of performed PA [45]; therefore, we do not believe that this is a significant source of bias. Even though we did not include PA in our analyses, the potential protective interaction between altitude and physical activity is an interesting hypothesis that goes far beyond this present study.

We could not separate the individuals and the coexistence of CVD, but when assessing the association excluding those with history of high blood pressure or highest values of cholesterol the association remained.

Other sources of potential residual confounding were the lack of information about pollution, humidity, temperature, and green space exposure. But, to our knowledge, most of those potential determinants of cardiovascular risk could not act as significant confounders as we found that the association was significant in all the sensitivity analyses.

Another limitation is related to the main quantitative nature of the study. Qualitative or mixed-methods tools could give an added value to the interpretation of the results as they provide further details of people's lifestyles, behaviours, and contexts.

In addition, we did not consider the effects and/or interactions of place of birth and climate related determinants, as it was impossible to determine them within the available survey data. As a previous study indicated [33], being born at altitudes higher or lower than the place of residence was associated with lower or higher risk. Additionally, other studies elucidated on the effects of climate related factors such as temperature and levels of ultraviolet radiation [46] which have a possible negative effect on cardiovascular mortality. Consequently, including these factors in further research,

could provide a better understanding of the risks, particularly important to the populations inhabiting the Andes.

Finally, information on food intake was not included in the survey questionnaire and information on occupation was not systematically collected. In the US population, the inverse association between altitude and obesity remained while adjusting for fruit and vegetable consumption [14].

### **Suggestions for future research**

It is necessary to elucidate on the epigenetic, molecular, and physiologic pathways to achieve protection against CVDs among people who live at higher altitudes. Regarding those protective mechanisms, several explanations have been proposed.

First, a study focused on assessing the effect of altitude training at 1600 and 1800 m showed larger improvements in performance after altitude training. It may be due to the greater overall load of training in hypoxia compared with normoxia, combined with a hypoxia-mediated increase in hemoglobin mass [47]. Nevertheless, there is uncertainty about the optimal timeframe for peak performances, suggesting that the optimal window to improve physical performance is individual, and factors other than altitude exposure per se may be important.

Second, it is also possible that other factors such as polymorphisms for high altitude adaptation were involved in this effect, Valverde and cols. identified a number of single nucleotide polymorphisms (SNPs) exhibiting large allele frequency differences over 900,000 genotyped SNPs. A region in chromosome 10 (within the cytogenetic bands q22.3 and q23.1) was significantly differentiated between highland and lowland groups [48], interestingly, the results suggest that positive selection on the enhancer might

383 increase the expression of this antioxidant, and thereby prevent oxidative damage. In  
384 addition, the most significant signal in a relative extended haplotype homozygosity  
385 analysis was localized to the SFTPD gene, which encodes a surfactant pulmonary-  
386 associated protein involved in normal respiration and innate host defence.

387 We believe that several potential issues to investigate would be relevant soon. There is a  
388 possibility that altitude induces expression of certain genes related to protective  
389 mechanisms against cardiovascular disease.

390 Moreover, we raised the question about how altitude could contribute to enhance the  
391 effects of population density-related features (pollution from urban areas, migrations or  
392 food accessibility) [18], several behavioural changes or treatments for primary  
393 prevention of cardiovascular risk and, even, for cardiovascular disease. In that regard,  
394 mortality may be profoundly modified by the complex interactions between behavioral  
395 and environmental conditions.

## 396 **Conclusion**

397 From a public health perspective, altitude at which individuals live is an important  
398 health determinant of cardiovascular risk; specifically, *per* each increase of 1000 m in  
399 the altitude that people live at, there is a reduction of almost half a percentual point in  
400 the cardiovascular risk at 10 years. It is important to consider that living in the  
401 highlands could be a protective factor related to a reduced cardiovascular risk, but this  
402 effect could be not as relevant from a clinical perspective than from a public health  
403 point of view. Further research is necessary to understand genetics, epigenetic, and  
404 molecular mechanisms that explain this finding; complemented by further analyses on  
405 environmental, climate and behavioural factors.



## 407 **Acknowledgments**

408 Authors thank the input from the “Cardiovascular Risk Score” project members. We,  
409 also, acknowledge the contributions from the *Instituto de Salud Pública* from PUCE.

## 410 **Author Contributions**

411 Conceptualization: Andrea Cevallos Guerrero, Heidi Angela Fernández, Ángela León-  
412 Cáceres, Luciana Armijos-Acurio, and Iván Dueñas-Espín

413 Data curation: Carmenza Sevilla and Iván Dueñas-Espín

414 Formal analysis: Iván Dueñas-Espín

415 Funding acquisition: Luciana Armijos-Acurio, Carlos Erazo, Ruth Jimbo-Sotomayor,  
416 Hugo Pereira-Olmos, Henry Pineda-Abarca, Erika Quishpe-Narváez, Xavier Sánchez,  
417 Carmenza Sevilla, Betzabé Tello, Ana Torres-Castillo, Tatiana Villacrés, and Iván  
418 Dueñas-Espín.

419 Investigation: Andrea Cevallos Guerrero, Heidi Angela Fernández, Ángela León-  
420 Cáceres, Luciana Armijos-Acurio, Carlos Erazo, Ruth Jimbo-Sotomayor, Hugo Pereira-  
421 Olmos, Henry Pineda-Abarca, Erika Quishpe-Narváez, Xavier Sánchez, Carmenza  
422 Sevilla, Betzabé Tello, Ana Torres-Castillo, Tatiana Villacrés, and Iván Dueñas-Espín.

423 Methodology: Iván Dueñas-Espín.

424 Project administration: Iván Dueñas-Espín.

425 Writing – original draft: Andrea Cevallos Guerrero, Heidi Angela Fernández, Ángela  
426 León-Cáceres, and Iván Dueñas-Espín.

427 Writing – review & editing: Andrea Cevallos Guerrero, Heidi Angela Fernández,  
 428 Ángela León-Cáceres, Luciana Armijos-Acurio, Carlos Erazo, Ruth Jimbo-Sotomayor,  
 429 Hugo Pereira-Olmos, Henry Pineda-Abarca, Erika Quishpe-Narváez, Xavier Sánchez,  
 430 Carmenza Sevilla, Betzabé Tello, Ana Torres-Castillo, Tatiana Villacrés, and Iván  
 431 Dueñas-Espín.

432

## 433    **References**

- 434    1.    World Health Organization. Global Status Report On Noncommunicable  
435       Diseases 2014. 2014;
- 436    2.    Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP,  
437       et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the  
438       American Heart Association. Vol. 139, Circulation. 2019. 56–528 p.
- 439    3.    Bloom DE, Cafiero E, Jané-Llopis E, Abrahams-Gessel S, Bloom LR, Fathima S,  
440       et al. The Global Economic Burden of Noncommunicable Diseases.  
441       2011;(September).
- 442    4.    World Health Organization (WHO). Cardiovascular diseases (CVDs) [Internet].  
443       2017 [cited 2021 Apr 13]. Available from: [https://www.who.int/en/news-](https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds))  
444       room/fact-sheets/detail/cardiovascular-diseases-(cvds)
- 445    5.    Berra K, Fletcher B, Hayman LL, Miller NH. Global cardiovascular disease  
446       prevention: A call to action for nursing executive summary. J Cardiovasc Nurs.  
447       2013;28(6):505–13.
- 448    6.    Martínez-García M, Salinas-Ortega M, Estrada-Arriaga I, Hernández-Lemus E,  
449       García-Herrera R, Vallejo M. A systematic approach to analyze the social  
450       determinants of cardiovascular disease. PLoS One. 2018;13(1):1–25.
- 451    7.    Roux AVD, Merkin SS, Arnett D, Chambless L, Massing M, Nieto FJ, et al.  
452       Neighborhood of Residence and Incidence of Coronary Heart Disease. N Engl J  
453       Med. 2001 Jul;345(2):99–106.
- 454    8.    Havranek EP, Mujahid MS, Barr DA, Blair I V., Cohen MS, Cruz-Flores S, et al.  
455       Social determinants of risk and outcomes for cardiovascular disease: A scientific

- statement from the American Heart Association. *Circulation*. 2015;132(9):873–98.
9. Ezzati M, Obermeyer Z, Tzoulaki I, Mayosi BM, Elliott P, Leon DA. Contributions of risk factors and medical care to cardiovascular mortality trends. *Nat Rev Cardiol*. 2015 Sep;12(9):508–30.
10. Baumgartner J, Brauer M, Ezzati M. The role of cities in reducing the cardiovascular impacts of environmental pollution in low- and middle-income countries. 2020;1–11.
11. Kretsoulas C, Anand SS. The impact of social determinants on cardiovascular disease. *Can J Cardiol* [Internet]. 2010;26(SUPPL. C):8C-13C. Available from: [http://dx.doi.org/10.1016/S0828-282X\(10\)71075-8](http://dx.doi.org/10.1016/S0828-282X(10)71075-8)
12. Rajagopalan S, Al-Kindi SG, Brook RD. Air Pollution and Cardiovascular Disease. *J Am Coll Cardiol*. 2018 Oct;72(17):2054–70.
13. Bhatnagar A. Environmental Determinants of Cardiovascular Disease. Vol. 121, *Circulation Research*. 2017. p. 162–80.
14. Woolcott OO, Gutierrez C, Castillo OA, Elashoff RM, Stefanovski D, Bergman RN. Inverse association between altitude and obesity: A prevalence study among andean and low-altitude adult individuals of Peru. *Obesity*. 2016;24(4):929–37.
15. Pérez-Galarza J, Baldeón L, Franco OH, Muka T, Drexhage HA, Voortman T, et al. Prevalence of overweight and metabolic syndrome, and associated sociodemographic factors among adult Ecuadorian populations: the ENSANUT-ECU study. *J Endocrinol Invest* [Internet]. 2021;44(1):63–74. Available from: <https://doi.org/10.1007/s40618-020-01267-9>



- 479 16. Song C, Chongsuvivatwong V, Zhu Luo Bu O, Ji D, Sang Zhuo Ma B, Sriplung  
480 H. Relationship between hypertension and geographic altitude: a cross-sectional  
481 survey among residents in Tibet. *J Int Med Res.* 2020;48(2).
- 482 17. Pajuelo-Ramírez J, Torres-Aparcana H, Agüero-Zamora R, Quispe AM. Altitude  
483 and its inverse association with abdominal obesity in an andean country: A cross-  
484 sectional study [version 1; peer review: 2 approved, 1 not approved].  
485 *F1000Research.* 2019;8:1–17.
- 486 18. Lopez-Pascual A, Bes-Rastrollo M, Sayón-Orea C, Perez-Cornago A, Díaz-  
487 Gutiérrez J, Pons JJ, et al. Living at a geographically higher elevation is  
488 associated with lower risk of metabolic syndrome: Prospective analysis of the  
489 SUN cohort. *Front Physiol.* 2017;7(JAN):1–9.
- 490 19. Rimoldi SF, Sartori C, Seiler C, Delacretaz E, Mattle HP, Scherrer U, et al. High-  
491 altitude exposure in patients with cardiovascular disease: Risk assessment and  
492 practical recommendations. *Prog Cardiovasc Dis* [Internet]. 2010;52(6):512–24.  
493 Available from: <http://dx.doi.org/10.1016/j.pcad.2010.03.005>
- 494 20. Seccombe LM, Peters MJ. Physiology in medicine: Acute altitude exposure in  
495 patients with pulmonary and cardiovascular disease. *J Appl Physiol.*  
496 2014;116(5):478–85.
- 497 21. Niermeyer S, Mollinedo PA, Huicho L. Child health and living at high altitude.  
498 Vol. 94, *Archives of Disease in Childhood.* 2009. p. 806–11.
- 499 22. Huddleston B, de Salvo EAP, Zanetti M, Bloise M, Bel J, Franceschini G, et al.  
500 Towards a GIS-based analysis of mountain environments and populations  
501 [Internet]. *Environment and Natural Resources working paper No. 10.* 2003  
502 [cited 2021 Apr 13]. Available from: <http://www.fao.org/family->

503 farming/detail/en/c/285416/

504 23. Savla JJ, Levine BD, Sadek HA. The Effect of Hypoxia on Cardiovascular  
505 Disease: Friend or Foe? High Alt Med Biol. 2018;19(2):124–30.

506 24. Mingji C, Onakpoya IJ, Perera R, Ward AM, Heneghan CJ. Relationship  
507 between altitude and the prevalence of hypertension in Tibet: A systematic  
508 review. Heart. 2015;101(13):1054–60.

509 25. Ezzati M, Horwitz MEM, Thomas DSK, Friedman AB, Roach R, Clark T, et al.  
510 Altitude, life expectancy and mortality from ischaemic heart disease, stroke,  
511 COPD and cancers: National population-based analysis of US counties. J  
512 Epidemiol Community Health. 2012;66(7).

513 26. Freire W, Ramírez-Luzuriaga M, Belmont P, Mendieta M, Silva-Jaramillo M,  
514 Romero N, et al. Instituto Nacional de Estadística y Censos INEC, Ministerio de  
515 Salud Pública MSP. Encuesta Nacional de salud y Nutrición. ENSANUT-ECU  
516 2012. Quito-Ecuador: Ministerio de Salud Pública. Instituto Nacional de  
517 Estadísticas y Censos; 2014. p. 112.

518 27. Statements P. Standards of medical care in diabetes - 2012. Diabetes Care.  
519 2012;35(SUPPL. 1).

520 28. Anderson KM, Odell PM, Wilson PWF, William B. Kannel M. Cardiovascular  
521 disease risk profiles. Am Heart J. 1991;(1).

522 29. Tunstall-Pedoe H. Cardiovascular risk and risk scores: ASSIGN, Framingham,  
523 QRISK and others: How to choose. Heart. 2011;97(6):442–4.

524 30. Marrugat J, Vila J, Pavesi M, Sanz F. [Estimation of the sample size in clinical  
525 and epidemiological investigations]. Med Clin (Barc) [Internet]. 1998 Sep

- 12;111(7):267–76. Available from:  
<http://www.ncbi.nlm.nih.gov/pubmed/9789243>
31. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018  
AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCN  
A Guideline on the Management of Blood Cholesterol: A Report of the American  
College of Cardiology/American Heart Association Task Force on Clinical  
Practice Guidelines. Vol. 139, Circulation. 2019. 1082–1143 p.
32. Burtcher M. Effects of living at higher altitudes on mortality: A narrative  
review. Aging Dis. 2014;5(4):274–80.
33. Faeh D, Gutzwiller F, Bopp M. Lower mortality from coronary heart disease and  
stroke at higher altitudes in Switzerland. Circulation. 2009;120(6):495–501.
34. Baibas N, Trichopoulou A, Voriadis E, Trichopoulos D. Residence in  
mountainous compared with lowland areas in relation to total and coronary  
mortality. A study in rural Greece. J Epidemiol Community Health. 2005;59(4):274–8.
35. Hultgren HN. Effects of altitude upon cardiovascular diseases. J Wilderness Med  
[Internet]. 1992;3(3):301–8. Available from: <http://dx.doi.org/10.1580/0953-9859-3.3.301>
36. Corante N, Anza-Ramírez C, Figueroa-Mujica R, MacArlupú JL, Vizcardo-  
Galindo G, Bilo G, et al. Excessive Erythrocytosis and Cardiovascular Risk in  
Andean Highlanders. High Alt Med Biol. 2018;19(3):221–31.
37. Negi PC, Bhardwaj R, Kandoria A, Asotra S, Ganju N, Marwaha R, et al.

549 Epidemiological study of hypertension in natives of Spiti valley in Himalayas  
550 and impact of hypobaric hypoxemia; A cross-sectional study. J Assoc Physicians  
551 India. 2012;60(6):21–5.

552 38. Azad P, Zhao HW, Cabrales PJ, Ronen R, Zhou D, Poulsen O, et al. Senp1 drives  
553 hypoxia-induced polycythemia via GATA1 and Bcl-xL in subjects with Monge's  
554 disease. J Exp Med. 2016;213(12):2729–44.

555 39. Naeije R, De Backer D, Vachiéry JL, De Vuyst P. High-altitude pulmonary  
556 edema with primary pulmonary hypertension. Chest [Internet]. 1996;110(1):286–  
557 9. Available from: <http://dx.doi.org/10.1378/chest.110.1.286>

558 40. Sherpa LY, Deji, Stigum H, Chongsuvivatwong V, Thelle DS, Bjertness E.  
559 Obesity in Tibetans aged 30–70 living at different altitudes under the North and  
560 South faces of Mt. Everest. Int J Environ Res Public Health. 2010;7(4):1670–80.

561 41. Miele CH, Schwartz AR, Gilman RH, Pham L, Wise RA, Davila-Roman VG, et  
562 al. Increased Cardiometabolic Risk and Worsening Hypoxemia at High Altitude.  
563 High Alt Med Biol. 2016;17(2):93–100.

564 42. Aryal N, Weatherall M, Bhatta YKD, Mann S. Blood pressure and hypertension  
565 in people living at high altitude in Nepal. Hypertens Res [Internet].  
566 2019;42(2):284–91. Available from: <http://dx.doi.org/10.1038/s41440-018-0138->  
567 x

568 43. Assari S, Nikahd A, Malekahmadi MR, Lankarani MM, Zamanian H. Race by  
569 Gender Group Differences in the Protective Effects of Socioeconomic Factors  
570 Against Sustained Health Problems Across Five Domains. J Racial Ethn Heal  
571 Disparities [Internet]. 2017;4(5):884–94. Available from:  
572 <http://dx.doi.org/10.1007/s40615-016-0291-3>

- 573 44. Dégano IR, Marrugat J, Grau M, Salvador-González B, Ramos R, Zamora A, et  
574 al. The association between education and cardiovascular disease incidence is  
575 mediated by hypertension, diabetes, and body mass index. *Sci Rep*. 2017;7(1):1–  
576 8.
- 577 45. Zaccagni L, Barbieri D, Cogo A, Gualdi-Russo E. Anthropometric and body  
578 composition changes during expeditions at high altitude. *High Alt Med Biol*.  
579 2014;15(2):176–82.
- 580 46. Burtcher M, Burtcher J. Concerning the article recently published in this  
581 Journal by Aryal and colleagues entitled, “Blood pressure and hypertension in  
582 people living at high altitude in Nepal.” *Hypertens Res* [Internet].  
583 2019;42(7):1095. Available from: <http://dx.doi.org/10.1038/s41440-019-0241-7>
- 584 47. Sharma AP, Saunders PU, Garvican-Lewis LA, Clark B, Welvaert M, Gore CJ,  
585 et al. Improved performance in national-level runners with increased training  
586 load at 1600 and 1800 m. *Int J Sports Physiol Perform*. 2019;14(3):286–95.
- 587 48. Valverde G, Zhou H, Lippold S, De Filippo C, Tang K, Herráez DL, et al. A  
588 novel candidate region for genetic adaptation to high altitude in Andean  
589 populations. *PLoS One*. 2015;10(5):1–22.

590

## 591 Tables and Figures

592 Table 1. Description of the sample across altitude categories.

Variable	Altitude in m (n = 3661)				p-value
	0 to 53 n=919	54 to 843 n=914	844 to 2635 n=914	2636 to 3834 n=914	
Female sex, n (%)	604 (24)	634 (25)	647 (26)	647 (26)	0.061**
Age, mean (SD)	46 (7)	44 (8)	45 (7)	45 (7)	<0.001*
Ethnicity					
Indigenous, n (%)	11 (3)	107(32)	83 (25)	136 (40)	<0.001**
Afroecuadorians, n (%)	89 (56)	47 (29)	11 (7)	13 (8)	
Montubio, n (%)	61 (50)	54 (44)	3 (2)	4 (3)	
Mestizo, n (%)	758 (25)	706 (23)	817 (27)	761 (25)	
Education level					
Higher than secondary education, n %	198 (33)	92 (15)	159 (27)	147 (25)	<0.001**
Secondary education, n %	342 (27)	307 (25)	312 (25)	283 (23)	
Primary or lesser education, n %	379 (21)	515 (28)	443 (24)	484 (27)	
Social security availability, n (%)	318 (25)	299 (24)	347 (27)	300 (24)	0.063**
Any immigrant in the family (no immigrant is the ref.)	8 (12)	10 (15)	22 (33)	27 (40)	0.001**
Rural area (urban is the ref)	161 (12)	442 (32)	366 (26)	423 (30)	<0.001**
Income quintiles					
First quintile (the poorer group), n (%)	146 (18)	271 (34)	175 (22)	210 (26)	<0.001**
Second quintile, n (%)	157 (22)	241 (33)	181(25)	141(20)	
Third quintile, n (%)	209 (29)	210 (29)	168 (23)	139 (19)	
Fourth quintile, n (%)	237(33)	120 (17)	179 (25)	177 (25)	
Fifth quintile (the richest), n (%)	168 (24)	70 (10)	211(30)	247(35)	
≥ 7 members in the family, n (%)	130 (21)	212 (35)	136 (22)	133 (22)	<0.001**
Harmful habits					
Alcohol consumption, n (%)	839 (26)	799 (24)	823 (25)	806 (25)	0.041**
Tobacco smoking, n (%)	452 (28)	407 (25)	415 (25)	369 (22)	<0.002**
Comorbidities					
History of hypertension, n (%)	675 (24)	664 (24)	712 (26)	713 (26)	0.014*
History of diabetes, n (%)	848 (24)	867 (25)	880 (25)	885 (25)	<0.001*
Anthropometry					
Weight in Kg, mean (SD)	69 (13)	69 (13)	68 (12)	66 (12)	<0.001*
Height in cm, mean (SD)	156 (9)	156 (9)	154 (8)	154 (8)	0.119*
BMI in Kg/m2, mean (SD)	28.36 (5)	28.29 (5)	28.58 (4)	27.90 (4)	<0.001*
≥18.5 to <25, n (%)	202 (26)	204 (26)	167 (22)	199 (26)	0.087
<18, n (%)	6 (35)	3 (18)	3 (18)	5 (29)	
25 to <30, n (%)	376 (25)	346 (23)	400 (26)	409 (27)	
≥ 30, n (%)	277 (26)	258 (25)	278 (27)	237 (23)	
Systolic pressure, mean (SD)	125 (17)	122 (16)	121 (16)	121 (15)	0.001*
Diastolic pressure, mean (SD)	77 (10)	76 (11)	75 (10)	75 (10)	0.057*
Laboratory Tests					
Hematocrit in %, mean (SD)	41 (4)	41 (4)	43 (4)	45 (4)	0.633*
Glucose in mg/dL, mean (SD)	105 (50)	95 (34)	93 (34)	94 (28)	<0.001*
Total cholesterol in mg/dL, mean (SD)	201 (46)	193 (39)	195 (39)	197 (39)	<0.001*

<i>LDL in mg/dL, mean (SD)</i>	123 (36)	116 (33)	118 (32)	119 (33)	<0.001*
<i>HDL in mg/dL, mean (SD)</i>	47 (13)	45 (13)	45 (13)	46 (14)	0.030*
<i>Triglycerides in mg/dL, mean (SD)</i>	163 (165)	166 (125)	169 (152)	167 (118)	<0.001*
Cardiovascular risk at 10 years in %					
<i>Risk of CVD, P50 (P25 to P75)</i>	8 (4 to 15)	7 (4 to 15)	7 (3 to 13)	6 (3 to 12)	<0.001***
<i>Risk of stroke or CHD, P50 (P25 to P75)</i>	7 (3 to 13)	5 (3 to 11)	6 (3 to 10)	5 (3 to 10)	<0.001***
Notes: * ANOVA ** Chi2 *** Kruskal Wallis Abbreviations: CI, confidence interval; N/A, not applicable, CHD, coronary heart disease; CVD, cardiovascular disease; BMI, body mass index					

593


594 Table 2. Crude and adjusted associations between altitude and the risk of stroke and/or CHD at 10 years (linear regression model).

Variable	Crude		Adjusted			
	$\beta$ (95% CI)	p-value	Saturated Model* $\beta$ (95% CI)	p-value	Parsimonious Model** $\beta$ (95% CI)	p-value
Constant	N/A	-	14.22 (11.68 to 16.76)	<0.001	13.62 (12.62 to 14.67)	<0.001
Altitude (per each extra meter)	-0.0005 (-0.0007 to -0.0003)	<0.001	-0.0004 (-0.0006 to -0.0003)	<0.001	-0.0005 (-0.0006 to -0.0003)	<0.001
Female (male is the ref.)	-8.04 (-8.46 to -7.61)	<0.001	-6.23 (-6.63 to -5.83)	<0.001	-6.24 (-6.64 to -5.84)	<0.001
Age (per each extra year)	0.69 (0.65 to 0.74)	<0.001	0.60 (0.57 to 0.63)	<0.001	0.59 (0.56 to 0.62)	<0.001
Ethnicity						
Indigenous (ref.)	N/A	-	N/A	-	N/A	-
Afroecuadorians	2.73 (1.32 to 4.14)	<0.001	0.93 (0.04 to 1.82)	0.042	0.96 (0.07 to 1.85)	0.035
Montubio	3.7 (2.16 to 5.20)	<0.001	0.52 (-0.44 to 1.47)	0.287	0.51 (-0.44 to 1.46)	0.295
Mestizo	2.90 (2.04 to 3.76)	<0.001	0.91 (0.35 to 1.47)	<0.001	0.94 (0.38 to 1.49)	0.001
Education level						
Higher than secondary education (ref.)	N/A	-	N/A	-	N/A	-
Secondary education	-0.07 (-0.79 to 0.64)	0.841	-0.09 (-0.55 to 0.37)	0.697	-	-
Less than Primary education	0.01 (-0.66 to 0.68)	0.972	-0.36 (-0.85 to 0.13)	0.151	-	-
Social security availability (not having is the ref.)	1.24 (0.74 to 1.73)	<0.001	-0.42 (-0.74 to -0.10)	0.010	-0.40 (-0.71 to -0.09)	0.011
Any immigrant in the family (no immigrant is the ref.)	-0.65 (-2.41 to 1.10)	0.465	0.05 (-1.02 to 1.11)	0.931	-	-
Rural area (urban is the ref)	-0.99 (-1.48 to -0.50)	<0.001	-0.22 (-0.58 to 0.14)	0.225	-	-
Income quintile						
First quintile (the poorer group is the ref.)	N/A	-	N/A	-	N/A	-
Second quintile	2.02 (1.27 to 2.77)	<0.001	0.83 (0.36 to 1.30)	0.001	0.91 (0.45 to 1.38)	<0.001
Third quintile	2.38 (1.63 to 3.12)	<0.001	0.81 (0.31 to 1.31)	0.002	0.99 (0.52 to 1.46)	<0.001
Fourth quintile	2.21 (1.47 to 2.96)	<0.001	0.65 (0.12 to 1.19)	0.017	0.92 (0.44 to 1.40)	<0.001
Fifth quintile (the richest)	1.91 (1.16 to 2.65)	<0.001	0.93 (0.34 to 1.51)	0.002	1.29 (0.80 to 1.77)	<0.001
≥ 7 members in the family (otherwise is the ref.)	-0.38 (-1.02 to 0.25)	0.238	0.01 (-0.39 to 0.40)	0.971	-	-
Any alcohol consumption	3.36 (2.56 to 4.16)	<0.001	0.90 (0.40 to 1.40)	<0.001	0.89 (0.39 to 1.39)	<0.001



(otherwise is the ref.)						
History of hypertension	2.64 (2.10 to 3.19)	<0.001	1.50 (1.15 to 1.84)	<0.001	1.50 (1.16 to 1.84)	<0.001
BMI, in Kg/m <sup>2</sup>						
≥18.5 to <25 (ref.)	N/A	-	N/A	-	N/A	-
<18	-2.30 (-5.66 to 1.06)	0.181	-1.17 (-3.21 to 0.87)	0.262	-1.11 (-3.15 to 0.93)	0.287
25 to <30	1.75 (1.14 to 2.35)	<0.001	1.19 (0.81 to 1.56)	<0.001	1.19 (0.82 to 1.56)	<0.001
≥30	2.31 (1.66 to 2.96)	<0.001	1.97 (1.55 to 2.38)	<0.001	1.97 (1.56 to 2.38)	<0.001
Hematocrit (per each extra % point)	0.58 (0.53 to 0.63)	<0.001	0.14 (0.09 to 0.18)	<0.001	0.14 (0.09 to 0.18)	<0.001
Triglycerides (per each extra unit in mg/dL)	0.02 (0.02 to 0.02)	<0.001	0.02 (0.01 to 0.02)	<0.001	0.02 (0.01 to 0.02)	<0.001
<p>Notes:</p> <p>* The value of the constant is the percentage of stroke risk and CHD at 10 years (according to Framingham equation) of a patient who lives in a mean altitude, is an indigenous person, not having social security, has higher than secondary education, who lives in an urban context, in who belongs to the first economic quintile, who has emigrant relatives, who lives with &lt;7 persons, who does not drink alcohol, and did not reported high blood pressure as a medical diagnosis, has body mass index between 18.5 to &lt;25 Kg/m<sup>2</sup>, has a mean hematocrit, and mean triglycerides concentration.</p> <p>** The value of the constant is the percentage of risk of stroke and CHD at 10 years (according to Framingham equation) of a patient who lives in a mean altitude, is an indigenous person, has higher than secondary education, who belongs to the first economic quintile, who does not drink alcohol, and did not reported high blood pressure as a medical diagnosis, has body mass index between 18.5 to &lt;25 Kg/m<sup>2</sup>, has a mean hematocrit, and mean triglycerides concentration.</p> <p>Abbreviations:</p> <p>CI, confidence interval; N/A, not applicable, CHD, coronary heart disease; CVD, cardiovascular disease; BMI, body mass index</p>						

596 Figure 1. Adjusted odds ratios of high risk ( $\geq 20\%$ ) of stroke and/or CHD and high risk  
597 of CVD at 10 years by altitude categories, according to two multivariate logistic  
598 regression models, considering the reference an altitude of the residence of  $<54$  m.



## 601    **Supporting information**

602    **S1 Fig. Flowchart diagram.**

603    **S2 Fig. Histogram of altitude.**

604    **S3. Fig. Histogram of Cardiovascular risk at ten years of stroke and coronary**  
605    **heart disease.**

606    **S1 Table. Characteristics of 3661 participants of Ecuadorian NHS included in the**  
607    **analyses.**

608    **S2 Table. Crude and adjusted Odds Ratios of high cardiovascular risk, calculated**  
609    **by four different equations, across altitude strata, according to multivariate**  
610    **logistic regression models.**

611    **S3 Table. Crude and adjusted associations between altitude and the risk of stroke**  
612    **and/or CHD at 10 years (linear regression model) stratified by sex.**

613    **S4 Table. Crude and adjusted associations between altitude and the risk of stroke**  
614    **and/or CHD at 10 years (linear regression models) excluding: (i) those who were**  
615    **living less than 53 m, (ii) those who were living higher than 2635 m, (iii) those with**  
616    **self-reported diagnosis of hypertension, and (iv) those with elevated LDL**  
617    **cholesterol ( $\geq 160$  mg/dL).**

